

1 **SEVERE COVID-19 IS MARKED BY DYSREGULATED SERUM LEVELS OF**
2 **CARBOXYPEPTIDASE A3 AND SEROTONIN**

3
4 Rodolfo Soria-Castro^{1‡}, Yatsiri G. Meneses-Preza^{1‡}, Gloria M. Rodríguez López^{1‡},
5 Sandra Romero-Ramírez^{2,3}, Víctor A. Sosa-Hernandez^{2,4}, Rodrigo Cervantes-Díaz^{2,3},
6 Alfredo Pérez-Fragoso⁵, José J. Torres-Ruíz⁶, Diana Gómez-Martín⁵, Marcia Campillo-
7 Navarro⁷, Violeta D. Álvarez-Jiménez⁸, Sonia M. Pérez-Tapia^{1,9}, Alma D. Chávez-
8 Blanco¹⁰, Sergio Estrada-Parra¹, José L. Maravillas-Montero^{2*} and Rommel Chacón
9 Salinas^{1*}.

10
11 **Article type:** Brief conclusive report

12 **Key words:** Mast cell, carboxypeptidase A3, serotonin, SARS-CoV-2, COVID-19.

13
14 1. Departamento de Inmunología, Escuela Nacional de Ciencias Biológicas, Instituto
15 Politécnico Nacional, ENCB-IPN. Mexico City, Mexico.

16 2. Red de Apoyo a la Investigación, Universidad Nacional Autónoma de México e
17 Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico city,
18 Mexico.

19 3. Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico city,
20 Mexico.

21 4. Departamento de Biomedicina Molecular, Centro de Investigación y de Estudios
22 Avanzados del Instituto Politécnico Nacional, Mexico City, Mexico.

23 5. Departamento de Inmunología y Reumatología, Instituto Nacional de Ciencias
24 Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.

- 25 6. Departamento de Atención Institucional Continua y Urgencias, Instituto Nacional de
26 Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
- 27 7. Research Coordination, Centro Médico Nacional 20 de Noviembre, ISSSTE, Mexico
28 City, Mexico
- 29 8. Lab. de Biología Molecular y Bioseguridad Nivel 3. Centro Médico Naval-SEMAR,
30 Mexico city, Mexico
- 31 9. Unidad de Desarrollo e Investigación en Bioprocesos (UDIBI), Escuela Nacional de
32 Ciencias Biológicas, Instituto Politécnico Nacional, ENCB-IPN. Mexico City, Mexico
- 33 10. División de Ciencia Básica, Instituto Nacional de Cancerología (INCan). Mexico City,
34 Mexico

35

36 ‡ These authors have contributed equally to this work

37 * Corresponding authors:

38 José L. Maravillas-Montero, Ph.D.

39 maravillas@cic.unam.mx

40

41 Rommel Chacón-Salinas, Ph.D.

42 rommelchacons@yahoo.com.mx

43

44 **Abstract**

45 The immune response plays a critical role in the pathophysiology of SARS-CoV-2
46 infection ranging from protection to tissue damage. This is observed in the development
47 of acute respiratory distress syndrome when elevated levels of inflammatory cytokines
48 are detected. Several cells of the immune response are implied in this dysregulated

49 immune response including innate immune cells and T and B cell lymphocytes. Mast
50 cells are abundant resident cells of the respiratory tract, able to rapidly release different
51 inflammatory mediators following stimulation. Recently, mast cells have been associated
52 with tissue damage during viral infections, but little is known about their role in SARS-
53 CoV-2 infection. In this study we examined the profile of mast cell activation markers in
54 the serum of COVID-19 patients. We noticed that SARS-CoV-2 infected patients
55 showed increased carboxypeptidase A3 (CPA3), and decreased serotonin levels in their
56 serum. CPA3 levels correlated with C-reactive protein, the number of circulating
57 neutrophils and quick SOFA. CPA3 in serum was a good biomarker for identifying
58 severe COVID-19 patients, while serotonin was a good predictor of SARS-CoV-2
59 infection. In summary, our results show that serum CPA3 and serotonin levels are
60 relevant biomarkers during SARS-CoV-2 infection, suggesting that mast cells are
61 relevant players in the inflammatory response in COVID-19, might represent targets for
62 therapeutic intervention.

63

64 **Introduction**

65 Coronavirus disease 2019 (COVID-19) is caused by the SARS-CoV-2 virus, which was
66 identified for the first time in Wuhan, China in late 2019. Since then, the virus has spread
67 across the globe infecting more than 100 million people and causing the death of 2.1
68 million infected individuals (1).

69 SARS-CoV-2 infects cells of the mucosa that express the angiotensin-converting
70 enzyme II or ACE2, which is particularly abundant in type II alveolar cells of the lung and
71 also expressed in other tissues (2). The COVID-19 infection has an incubation period of
72 3-7 days, generating moderate symptoms, such as head and muscle aches, sore throat,
73 nasal congestion, dry cough, fatigue and fever. However, 5-10% of infected patients
74 develop acute respiratory distress syndrome (ARDS), a serious complication that
75 causes respiratory failure leading to high mortality (3).

76 A relevant factor for the development of ARDS in patients with COVID-19 is the
77 exacerbated immune response triggered by the infection, reflected as a cytokine storm
78 in which different cytokines such as IL-1 β , IL-2, IL-4, IL-6, IL-10, IFN- γ and TNF- α are
79 elevated (4). Besides, COVID-19 patients are known to show profound alterations in cell
80 populations associated with the immune response against viruses, such as monocytes,
81 macrophages, neutrophils, NK cells, B lymphocytes, CD8 + T lymphocytes and memory
82 and regulatory CD4 + lymphocytes (5). However, how mast cells (MC) are affected by
83 SARS-CoV-2 is not well understood.

84 MC are tissue resident leukocytes derived from hematopoietic precursors, distributed
85 throughout the body and abundantly found along the respiratory tract (6). These cells
86 are characterized by presenting many cytoplasmic granules that contain different

87 chemical mediators released after activation. Among the molecules abundant in MC
88 granules are tryptase, carboxypeptidase, chymase, serotonin, histamine and TNF- α . MC
89 also produce other types of inflammatory mediators including prostaglandins,
90 leukotrienes and reactive nitrogen species. In addition, activated mast cells secrete
91 different *de novo* synthesized cytokines and chemokines (7).

92 MC are well known for their role in mediating allergic reactions, but recent evidence
93 indicates an important role in the innate immune response to different pathogens
94 including viruses, bacteria, protozoa, fungi and nematodes (7). The ability of MC to
95 participate in viral infections is mediated by different Pattern Recognition Receptors,
96 such as TLR-3, -7, RIG-I, MDA-5, etc., which are essential in the innate antiviral
97 response (8). Recently, it was shown that mast cells are associated with tissue damage
98 induced by an excessive inflammatory response during viral infections (9). For instance,
99 in influenza virus infections, the observed lung tissue damage is due to an excessive
100 inflammatory response characterized by the overproduction of cytokines and
101 chemokines or 'cytokine storm' (10). In murine models of infection with the H5N1
102 influenza virus, treatment of mice with ketotifen, an inhibitor of mast cell activation,
103 reduces damage to lung tissue. Further, the combination of ketotifen with oseltamivir, an
104 antiviral drug, significantly increased mice survival (11). On the other hand, it has been
105 observed that mice deficient in MC show less lung damage when infected with influenza
106 A virus, compared to wild-type mice. Interestingly, this effect was associated with a
107 decreased production of TNF- α , CCL2, CCL3, CCL4, CXCL2 and CXCL10, suggesting
108 a crucial role of MC in the 'cytokine storm' triggered by influenza infection (12).

109 Considering that mast cell activation plays a crucial role during the damage induced by

110 viral infections and that cytokine storm is a crucial feature during SARS-CoV-2 infection,
111 this study was conducted to evaluate mast cell activation markers in the serum of
112 patients with COVID-19 and determine if they are associated with disease severity.
113

114 **MATERIAL AND METHODS**

115 **Patients and control**

116 Patients with COVID-19 and control group were enrolled at Instituto Nacional de
117 Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, between March-April 2020.
118 All participants in this study had COVID-19 suggestive symptoms, but only those
119 showing a positive PCR test for SARS-CoV-2 were considered infected, while PCR
120 negative patients were selected as control. Samples from asthmatic, HIV, cancer,
121 autoimmune or pregnant patients were not included in this study. Serum samples were
122 taken upon admission. Demographic and clinical parameters were collected, and
123 laboratory indicators were tested with conventional methods in COVID-19 patients
124 (Supplementary Table 1). Disease severity was classified as Mild/Moderate when
125 patients showed fever, signs of airway disease, with or without a tomographic image
126 indicating pneumonia. Severe COVID-19 patients showed either respiratory failure, an
127 increased respiratory rate (>30 bpm), decreased oxygen saturation at rest (<92%) or
128 decreased PaO₂/FiO₂ (<300 mmHg). This study was approved by the Research and
129 Ethics Committee of the Instituto Nacional de Ciencias Médicas y Nutrición Salvador
130 Zubirán (Ref. 3341). All protocols were in accordance with the Declaration of Helsinki.
131 All participants of this study signed an informed consent form to participate in this study.

132

133 **Assessment of mast cell activation markers**

134 Patient serum was analyzed by ELISA with commercial kits for histamine (Cat.
135 RE59221, IBL International, Germany), human carboxypeptidase A3 (Cat. OKCD01671,
136 Aviva Systems Biology, USA), serotonin (Cat. ab133053, Abcam, UK) and heparin (Cat.
137 abx 258893, Abbexa, USA), according to the manufacturer's instructions.

138 Nitric oxide was evaluated by a colorimetric method that measures the levels of the
139 breakdown product NO_2^- (Griess Reagent System, Cat. G2930, Promega, USA).

140

141 **IL-6 quantification**

142 IL-6 was evaluated with the Milliplex Map Human Cytokine/Chemokine Bead Panel-
143 Premixed 29 Plex (Cat. HCYTMAG-60K-PX29, Millipore, USA) following manufacturer's
144 instructions.

145

146 **Statistical analysis**

147 All statistical analyses were performed with SigmaPlot software version 14.0 (Systat
148 Software, San Jose, CA, USA). Data normality was assessed by Kolmogorov-Smirnov
149 with Lilliefors correction. Data are shown as mean or median \pm range, as appropriate.
150 For comparisons between two groups, Student's t-test or Mann-Whitney rank sum test
151 with Yates correction were used. For comparisons of three groups, one way-analysis of
152 variance (ANOVA) with Student-Newman-Keuls (SNK) post-hoc or Kruskal-Wallis test
153 followed by a Dunn's post-hoc test were used. Results were considered significant at a p
154 value <0.05 . For correlations of two variables, Spearman Rank Order Correlation was
155 used. The r values for each of the correlations were plotted in a bubble chart generated
156 with Microsoft Excel 2019 (<https://office.microsoft.com/excel>). Receiver operating
157 characteristic (ROC) curves were generated to find the accuracy of biomarkers to
158 distinguish infected individuals and the severity of COVID19.

159 **RESULTS AND DISCUSSION**

160 Several MC-derived biomarkers are used to diagnose and predict outcomes in allergic
161 and infectious diseases. Among them, histamine, heparin, carboxypeptidase A3 (CPA3),
162 serotonin, and nitric oxide have been studied (13, 14). To address whether these
163 markers are affected during COVID-19, serum samples were collected from patients
164 admitted at a tertiary care center in Mexico city. Demographic and clinical characteristics
165 of patients are shown in supplementary table 1. We noticed that COVID-19 patients
166 have increased levels of CPA3 in serum when compared to the control group (Figure
167 1A). Interestingly, serotonin showed decreased levels in serum of SARS-CoV-2 infected
168 patients compared to those not-infected (Figure 1B). Serum levels of histamine, heparin,
169 and nitric oxide were not affected in COVID-19 patients (Supplementary Figure 1).
170 Previous reports indicate that different immune markers are differentially expressed
171 during severe COVID-19 (15). Therefore, we investigated whether mast cell-derived
172 biomarkers were altered depending on COVID-19 severity. We observed that patients
173 with severe disease showed increased levels of CPA3 when compared to those with
174 mild/moderate disease, or individuals in the control group (Figure 1C). Serotonin levels
175 were decreased in severe COVID-19 (Figure 1D). No other mast cell-associated
176 biomarker evaluated showed significant difference in patients with severe COVID-19,
177 compared to patients with mild/moderate symptoms or controls (Supplementary Figure
178 2).

179 Because CPA3 and serotonin levels were altered in severe COVID-19 patients, we next
180 assessed their correlation with clinical and laboratory parameters. A matrix with
181 Spearman's r coefficient values and representing correlation showed that CPA3 had a
182 stronger correlation with an increased number of clinical and laboratory parameters in

183 comparison with serotonin (Figure 2A). Furthermore, CPA3 showed significant positive
184 correlation with inflammation associated markers as circulating neutrophils ($r=0.291$,
185 $p=0.0447$) (Figure 2B) and C-reactive protein ($r=0.390$, $p=0.00703$) (Figure 2D).
186 Remarkably, CPA3 also associated with disease severity score quick Sepsis-related
187 Organ Failure Assessment (qSOFA), ($r=0.335$, $p=0.00862$) (Figure 2C).
188 Finally, to evaluate the potential clinical utility of serotonin and CPA3, receiver-operator
189 characteristics (ROC) curves were performed to distinguish SARS-CoV-2 infection.
190 Serotonin showed an acceptable AUC (Area Under the Curve) values that allow to
191 distinguish between infected from non-infected individuals (AUC 0.77) (Figure 2E).
192 When ROC curves were analyzed to differentiate between mild/moderate and severe
193 COVID-19 patients, CPA3 (AUC 0.77) was more reliable than serotonin (AUC 0.58) or
194 IL-6 (AUC 0.56) to detect patients with severe disease. This was close to the predictive
195 values seen for C-reactive protein (AUC 0.93) (Figure 2F). As a whole, these results
196 suggest a relationship between mast cell activation, as reflected by CPA3 levels in
197 serum, and severe COVID-19.
198 To the best of our knowledge, this is the first evidence of alteration in serum serotonin
199 and CPA3 levels during COVID-19. CPA3 is abundantly expressed in human lungs (16),
200 with MC being the main cell source (Supplementary Figure 3). CPA3 is an enzyme that
201 cleaves C-terminal amino acid residues from proteins and is an abundant protein in MC
202 granules ($16 \mu\text{g CPA3 per } 10^6 \text{ MC}$). This enzyme is released after cell degranulation
203 and is associated with allergic pathologies of the respiratory tract (17). Identified
204 substrates for CPA3 include neurotensin, kinetensin, neuromedin N, angiotensin I and
205 endothelin-1, which is associated with pulmonary fibrosis (18), a sequela observed in

206 COVID-19 patients (19). Interestingly, we noticed that CPA3 correlated with clinical
207 parameters associated with systemic inflammation during COVID-19. Remarkably,
208 CPA3 correlated with circulating neutrophils and CPR, which are associated with an
209 exacerbated inflammatory response during COVID-19 (15). Previous studies have
210 noticed the importance of MC activation for the recruitment of neutrophils to sites of
211 infection (20). Furthermore, this increase in tissue neutrophil is proposed as one
212 mechanism of tissue damage and organ failure during COVID-19 (21). Our results are in
213 agreement with a recent histologic study, where an increased number of MC in the lungs
214 of COVID-19 patients was observed (22). These results suggest an important role of MC
215 in SARS-CoV-2 infection, but further work is needed to understand the mechanisms
216 involved.

217 The second marker that was modified during SARS-CoV-2 infection was serotonin.
218 Traditionally serotonin is considered as an important neurotransmitter regulating several
219 neuronal activities in the central nervous system. However, recent evidence indicates
220 that systemic serotonin distributed by the blood plays a more complex function in the
221 organism. Blood serotonin is produced by different cell lineages, including MC, but is
222 mainly produced by enterochromaffin cells of the intestine. Once in the blood, serotonin
223 levels are primarily regulated by platelets which capture and store in dense granules
224 which are secreted after cell activation (23). Previous studies have shown that infections
225 can decrease, increase or maintain serotonin levels in blood (24-26). For instance, in
226 dengue infection decreased levels of serum serotonin were associated with disease
227 severity. Moreover, a correlation is observed between decreased serotonin and
228 thrombocytopenia, a clinical feature of severe dengue, associating decreased serum
229 serotonin with decreased numbers of platelets (24, 26). However, we did not observe a

230 difference in platelet count in COVID-19 patients (Supplementary Table 1), implying
231 other mechanisms could be involved in this decrease. A recent report noticed that
232 platelet numbers are not affected in COVID-19, but their gene expression profile is
233 different when compared with those from healthy individuals (27). Because platelets
234 usually introduce serotonin from blood through a transporter (SERT or SLC6A4) (28), an
235 overexpression of this protein could explain the decrease of serotonin in blood.
236 However, Manne *et al* showed that SERT is not modified in platelets from COVID-19
237 patients (27). Another explanation could be related to an alteration in enterochromaffin
238 cells functions by SARS-CoV-2, a phenomenon that is observed in other viral infections
239 (29), or to increased serotonin degradation by monoamine oxidase (23), which is
240 overexpressed by platelets in COVID-19 patients (27). How this serotonin decrease can
241 affect the pathophysiology of SARS-CoV-2 infection is unknown; however among the
242 diverse functions of blood serotonin, one involves the modulation of immune response.
243 Several cells of the immune system express serotonin receptors, including those that
244 participate in innate and adaptive immune response (23). Activation of serotonin
245 receptor 5-HT_{2A} diminishes inflammation induced by TNF- α (30). Furthermore,
246 serotonin downmodulates IL-6 and TNF- α production by macrophages and lymphocytes
247 (31), suggesting the importance of serotonin in regulating exacerbated inflammation.
248 In conclusion, our results demonstrate that serum levels of CPA3 and serotonin are
249 affected during SARS-CoV-2 infection and can be considered as biomarkers during
250 COVID-19. We suggest that mast cells play an important role in this disease and that
251 these cells could be considered targets for therapeutic intervention.

252 **AUTORSHIP**

253 RS-C, YGM-P and GMR-L contributed equally to this work, designed, performed
254 experiments, analyzed data and drafted the manuscript. SR-R, VAS-H, RC-D, AP-F,
255 JJT-R, DG-M assisted in processing and preservation of patient samples, collected
256 patient data, generated, and organized clinical database. MC-N, VDA-J, SMP-T, ADC-B,
257 SE-P, JLM-M and RC-S analyzed, interpreted data, and drafted the manuscript. JLM-M
258 and RC-S designed, supervised the study and obtained funding. All authors critically
259 revised and approved the final version of this manuscript.

260

261 **ACKNOWLEDGMENTS**

262 We want to thank Dr Eduardo Ramírez San Juan for his invaluable advice for the
263 statistical analysis of our study, Fabián Flores-Borja for critical reading of the
264 manuscript, and Araceli Olvera G. for secretarial assistance. This study was supported
265 by CONACyT (F0005-2020-01-313252) to JLM-M, and (F0005-2020-01-312326) to RC-
266 S, and Secretaría de Investigación y Posgrado del IPN (SIP-IPN).

267

268 **DISCLOSURE**

269 The authors declare no conflicts of interest.


270 The data supporting the conclusions of this article will be made available by the authors
271 upon reasonable request.

272

273

274 **Figures**

275



276


277 **Figure 1. Serotonin and carboxypeptidase A3 are altered in COVID-19 patients.**

278 The serum concentration of A, C) Carboxypeptidase A3 (CPA3), and B, D) Serotonin

279 were measured upon patient admission by ELISA. Data from 21 patients with

280 mild/moderate disease, 41 patients with severe COVID-19, and 10 control individuals is

281 shown. Data are presented as mean or median \pm range, as appropriate. * $p < 0.05$; ** $p <$
282 0.01. Student's t test (A) Mann-Whitney test (B), one-way ANOVA test (C) and Kruskal-
283 Wallis test (D)
284



285

286

287 **Figure 2. Serum levels of carboxypeptidase A3 correlates with clinical parameters**

288 **of disease severity in COVID-19 patients. A) Correlation matrix representing**

289 correlation carboxypeptidase A3 or serotonin serum levels with clinical and laboratory

290 parameters used to determine COVID-19 severity. Spearman's coefficient value r is

291 used as correlation descriptor, and the size of each circle symbolizes correlation

292 strength (color scale of red and blue indicates negative or positive correlation,

293 respectively). Correlation between serum concentration of carboxypeptidase A3 and B)

294 blood neutrophils, C) qSOFA, D) C-reactive protein. Value of Spearman's correlation (r)

295 and significant p values ($p < 0.05$) are shown. E) Receiver-operator characteristics (ROC)

296 curves of carboxypeptidase A3 (CPA3) and serotonin serum levels for the prediction of

297 SARS-CoV-2 infection. F) ROC curve of C-reactive protein (CRP), carboxypeptidase A3

298 (CPA3), serotonin and interleukin-6 (IL-6) in the prediction of COVID-19 severity.

299

300 REFERENCES

- 301 1. World Health Organization Coronavirus Disease (COVID-19) Dashboard. 2021.
302 <https://covid19.who.int/>. Last accessed date January 28, 2021.
- 303 2. Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition
304 of SARS-CoV-2 by full-length human ACE2. *Science*. 2020;367(6485):1444-8.
- 305 3. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and
306 clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan,
307 China: a descriptive study. *Lancet*. 2020;395(10223):507-13.
- 308 4. Han H, Ma Q, Li C, Liu R, Zhao L, Wang W, et al. Profiling serum cytokines in
309 COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. *Emerg*
310 *Microbes Infect*. 2020;9(1):1123-30.
- 311 5. Cao X. COVID-19: immunopathology and its implications for therapy. *Nat Rev*
312 *Immunol*. 2020.
- 313 6. Andersson CK, Mori M, Bjermer L, Lofdahl CG, Erjefalt JS. Novel site-specific
314 mast cell subpopulations in the human lung. *Thorax*. 2009;64(4):297-305.
- 315 7. Campillo-Navarro M, Chavez-Blanco AD, Wong-Baeza I, Serafin-Lopez J, Flores-
316 Mejia R, Estrada-Parra S, et al. Mast Cells in Lung Homeostasis: Beyond Type I
317 Hypersensitivity. *Curr Respir Med Rev*. 2014;10(2):115-23.
- 318 8. Marshall JS, Portales-Cervantes L, Leong E. Mast Cell Responses to Viruses and
319 Pathogen Products. *Int J Mol Sci*. 2019;20(17).
- 320 9. Rathore AP, St John AL. Protective and pathogenic roles for mast cells during
321 viral infections. *Curr Opin Immunol*. 2020;66:74-81.
- 322 10. Kobasa D, Jones SM, Shinya K, Kash JC, Copps J, Ebihara H, et al. Aberrant
323 innate immune response in lethal infection of macaques with the 1918 influenza virus.
324 *Nature*. 2007;445(7125):319-23.
- 325 11. Hu Y, Jin Y, Han D, Zhang G, Cao S, Xie J, et al. Mast cell-induced lung injury in
326 mice infected with H5N1 influenza virus. *J Virol*. 2012;86(6):3347-56.
- 327 12. Graham AC, Hilmer KM, Zickovich JM, Obar JJ. Inflammatory response of mast
328 cells during influenza A virus infection is mediated by active infection and RIG-I
329 signaling. *J Immunol*. 2013;190(9):4676-84.
- 330 13. Mendez-Enriquez E, Hallgren J. Mast Cells and Their Progenitors in Allergic
331 Asthma. *Front Immunol*. 2019;10:821.
- 332 14. Swindle EJ, Metcalfe DD. The role of reactive oxygen species and nitric oxide in
333 mast cell-dependent inflammatory processes. *Immunol Rev*. 2007;217:186-205.
- 334 15. Velavan TP, Meyer CG. Mild versus severe COVID-19: Laboratory markers. *Int J*
335 *Infect Dis*. 2020;95:304-7.
- 336 16. Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A, et al.
337 Proteomics. Tissue-based map of the human proteome. *Science*.
338 2015;347(6220):1260419.
- 339 17. Pejler G, Knight SD, Henningsson F, Wernersson S. Novel insights into the
340 biological function of mast cell carboxypeptidase A. *Trends Immunol*. 2009;30(8):401-8.
- 341 18. Pejler G. The emerging role of mast cell proteases in asthma. *Eur Respir J*.
342 2019;54(4).
- 343 19. George PM, Wells AU, Jenkins RG. Pulmonary fibrosis and COVID-19: the
344 potential role for antifibrotic therapy. *Lancet Respir Med*. 2020;8(8):807-15.

- 345 20. Malaviya R, Ikeda T, Ross E, Abraham SN. Mast cell modulation of neutrophil
346 influx and bacterial clearance at sites of infection through TNF-alpha. *Nature*.
347 1996;381(6577):77-80.
- 348 21. Chen XY, Huang MY, Xiao ZW, Yang S, Chen XQ. Lactate dehydrogenase
349 elevations is associated with severity of COVID-19: a meta-analysis. *Crit Care*.
350 2020;24(1):459.
- 351 22. Motta Junior JDS, Miggiolaro A, Nagashima S, de Paula CBV, Baena CP,
352 Scharfstein J, et al. Mast Cells in Alveolar Septa of COVID-19 Patients: A Pathogenic
353 Pathway That May Link Interstitial Edema to Immunothrombosis. *Front Immunol*.
354 2020;11:574862.
- 355 23. Herr N, Bode C, Duerschmied D. The Effects of Serotonin in Immune Cells. *Front*
356 *Cardiovasc Med*. 2017;4:48.
- 357 24. Cui L, Lee YH, Thein TL, Fang J, Pang J, Ooi EE, et al. Serum Metabolomics
358 Reveals Serotonin as a Predictor of Severe Dengue in the Early Phase of Dengue
359 Fever. *PLoS Negl Trop Dis*. 2016;10(4):e0004607.
- 360 25. Bennuru S, Lustigman S, Abraham D, Nutman TB. Metabolite profiling of
361 infection-associated metabolic markers of onchocerciasis. *Mol Biochem Parasitol*.
362 2017;215:58-69.
- 363 26. Cui L, Fang J, Ooi EE, Lee YH. Serial Metabolome Changes in a Prospective
364 Cohort of Subjects with Influenza Viral Infection and Comparison with Dengue Fever. *J*
365 *Proteome Res*. 2017;16(7):2614-22.
- 366 27. Manne BK, Denorme F, Middleton EA, Portier I, Rowley JW, Stubben C, et al.
367 Platelet gene expression and function in patients with COVID-19. *Blood*.
368 2020;136(11):1317-29.
- 369 28. Robson MJ, Quinlan MA, Blakely RD. Immune System Activation and
370 Depression: Roles of Serotonin in the Central Nervous System and Periphery. *ACS*
371 *Chem Neurosci*. 2017;8(5):932-42.
- 372 29. Hagbom M, Istrate C, Engblom D, Karlsson T, Rodriguez-Diaz J, Buesa J, et al.
373 Rotavirus stimulates release of serotonin (5-HT) from human enterochromaffin cells and
374 activates brain structures involved in nausea and vomiting. *PLoS Pathog*.
375 2011;7(7):e1002115.
- 376 30. Nau F, Jr., Yu B, Martin D, Nichols CD. Serotonin 5-HT2A receptor activation
377 blocks TNF-alpha mediated inflammation in vivo. *PLoS One*. 2013;8(10):e75426.
- 378 31. Kubera M, Maes M, Kenis G, Kim YK, Lason W. Effects of serotonin and
379 serotonergic agonists and antagonists on the production of tumor necrosis factor alpha
380 and interleukin-6. *Psychiatry Res*. 2005;134(3):251-8.
- 381